GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166725 | Oral cavity | EOLP | response to nutrient levels | 82/2218 | 474/18723 | 2.59e-04 | 2.52e-03 | 82 |
GO:19021065 | Oral cavity | EOLP | negative regulation of leukocyte differentiation | 25/2218 | 102/18723 | 2.80e-04 | 2.69e-03 | 25 |
GO:00902872 | Oral cavity | EOLP | regulation of cellular response to growth factor stimulus | 57/2218 | 304/18723 | 2.84e-04 | 2.70e-03 | 57 |
GO:00026953 | Oral cavity | EOLP | negative regulation of leukocyte activation | 39/2218 | 187/18723 | 2.89e-04 | 2.74e-03 | 39 |
GO:20001466 | Oral cavity | EOLP | negative regulation of cell motility | 65/2218 | 359/18723 | 3.09e-04 | 2.89e-03 | 65 |
GO:005140324 | Oral cavity | EOLP | stress-activated MAPK cascade | 47/2218 | 239/18723 | 3.11e-04 | 2.91e-03 | 47 |
GO:00421132 | Oral cavity | EOLP | B cell activation | 61/2218 | 334/18723 | 3.68e-04 | 3.35e-03 | 61 |
GO:000717816 | Oral cavity | EOLP | transmembrane receptor protein serine/threonine kinase signaling pathway | 64/2218 | 355/18723 | 3.85e-04 | 3.46e-03 | 64 |
GO:004582421 | Oral cavity | EOLP | negative regulation of innate immune response | 19/2218 | 71/18723 | 4.53e-04 | 3.99e-03 | 19 |
GO:00510517 | Oral cavity | EOLP | negative regulation of transport | 80/2218 | 470/18723 | 5.11e-04 | 4.44e-03 | 80 |
GO:003629418 | Oral cavity | EOLP | cellular response to decreased oxygen levels | 34/2218 | 161/18723 | 5.40e-04 | 4.63e-03 | 34 |
GO:007147924 | Oral cavity | EOLP | cellular response to ionizing radiation | 19/2218 | 72/18723 | 5.48e-04 | 4.68e-03 | 19 |
GO:005067317 | Oral cavity | EOLP | epithelial cell proliferation | 75/2218 | 437/18723 | 5.90e-04 | 4.97e-03 | 75 |
GO:007030224 | Oral cavity | EOLP | regulation of stress-activated protein kinase signaling cascade | 39/2218 | 195/18723 | 6.89e-04 | 5.70e-03 | 39 |
GO:005101726 | Oral cavity | EOLP | actin filament bundle assembly | 33/2218 | 157/18723 | 7.04e-04 | 5.78e-03 | 33 |
GO:007145615 | Oral cavity | EOLP | cellular response to hypoxia | 32/2218 | 151/18723 | 7.27e-04 | 5.93e-03 | 32 |
GO:003103218 | Oral cavity | EOLP | actomyosin structure organization | 39/2218 | 196/18723 | 7.64e-04 | 6.12e-03 | 39 |
GO:007145318 | Oral cavity | EOLP | cellular response to oxygen levels | 36/2218 | 177/18723 | 7.88e-04 | 6.25e-03 | 36 |
GO:004814521 | Oral cavity | EOLP | regulation of fibroblast proliferation | 20/2218 | 80/18723 | 8.40e-04 | 6.56e-03 | 20 |
GO:00435061 | Oral cavity | EOLP | regulation of JUN kinase activity | 16/2218 | 58/18723 | 8.70e-04 | 6.75e-03 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RP1 | SNV | Missense_Mutation | novel | c.81G>C | p.Leu27Phe | p.L27F | P56715 | protein_coding | tolerated(0.65) | benign(0.007) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
RP1 | SNV | Missense_Mutation | rs747714373 | c.2978C>G | p.Ser993Cys | p.S993C | P56715 | protein_coding | deleterious(0.02) | possibly_damaging(0.781) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
RP1 | SNV | Missense_Mutation | | c.4362C>A | p.Ser1454Arg | p.S1454R | P56715 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-A2-A0CW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
RP1 | SNV | Missense_Mutation | novel | c.1138N>T | p.Pro380Ser | p.P380S | | protein_coding | deleterious(0.04) | probably_damaging(0.923) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RP1 | SNV | Missense_Mutation | novel | c.983N>G | p.Lys328Arg | p.K328R | | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-A7-A4SF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
RP1 | SNV | Missense_Mutation | | c.2516N>C | p.Gln839Pro | p.Q839P | P56715 | protein_coding | deleterious(0.03) | possibly_damaging(0.641) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RP1 | SNV | Missense_Mutation | novel | c.4466C>T | p.Ala1489Val | p.A1489V | P56715 | protein_coding | tolerated(0.22) | benign(0.01) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR |
RP1 | SNV | Missense_Mutation | | c.2675N>T | p.Ala892Val | p.A892V | P56715 | protein_coding | tolerated(0.14) | benign(0.039) | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
RP1 | SNV | Missense_Mutation | | c.1895N>T | p.Ser632Leu | p.S632L | P56715 | protein_coding | tolerated(0.2) | benign(0.042) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
RP1 | SNV | Missense_Mutation | | c.4027N>A | p.Asp1343Asn | p.D1343N | P56715 | protein_coding | tolerated(0.07) | benign(0) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |